2765852-46-6
Chemical Structure
BTK-IN-11
- CAS No.: 2765852-46-6
- Formula:C26H22ClN5O3
- Molecular Weight:487.94
IUPAC Name: 9'-(2-chloro-4-phenoxybenzoyl)-1-methyl-4',7'-dihydrospiro[pyrrolidine-3,2'-pyrrolo[3',2':5,6]pyrido[3,4-b]pyrazin]-3'(1'H)-one
InChIKey: AFMCTOKRAXKKBC-UHFFFAOYSA-N
SMILES: CN1CCC2(NC3=C4C(C(C5=CC=C(C=C5Cl)OC6=CC=CC=C6)=O)=CNC4=NC=C3NC2=O)C1
Biological Activity: BTK-IN-11 is a potent inhibitor of BTK. BTK plays an important role in signaling mediated by B cell antigen receptor (BCR) and Fcγreceptor (FcγR) in B cells and myeloid cells, respectively. BTK-IN-11 has the potential for the research of related diseases, especially autoimmune diseases, inflammatory diseases or cancer (extracted from patent WO2022063101A1, compound Z2)[1].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
BTK-IN-11 | BTK-IN-11 is a potent inhibitor of BTK. BTK plays an important role in signaling mediated by B cell antigen receptor (BCR) and Fcγreceptor (FcγR) in B cells and myeloid cells, respectively. BTK-IN-11 has the potential for the research of related diseases, especially autoimmune diseases, inflammatory diseases or cancer (extracted from patent WO2022063101A1, compound Z2). | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
Keywords
